[Prevention of myelotoxicity in a case of bone marrow transplantation using granulocyte-macrophage colony-stimulating factor along with ganciclovir].
We report the first experience of the use of GM-CSF as prophylaxis of ganciclovir induced severe bone marrow suppression in a CMV seropositive patient with acute myeloid leukemia who underwent a complete remission after an allogeneic bone marrow transplantation from an identical HLA sibling who also was CMV seropositive. A successful bone marrow engraftment was documented by day 14. Once peripheral blood counts stabilized, the patient received ganciclovir 5 mg/kg TIW. By day 73 severe neutropenia was documented but a spontaneous improvement occurred with discontinuation of ganciclovir. From day 100 to day. 110 he received daily ganciclovir at a dose of 5 mg/kg and the same dose of GM-CSF without signs of toxicity. There was no evidence of either acute graft versus host disease or of CMV infection. One year after transplantation he relapsed and died of complications of acute leukemia.
Reynoso Gómez
E
E
Depto. de Hematología, Instituto Nacional de Cancerología, México, D.F.
Dueñas González
A
A
Miranda López
E
E
Sobrevilla Calvo
P
P
Donis Hernández
J
J
Texcocano Becerra
J
J
Salinas Rojas
V
V
D000328:Adult; D016026:Bone Marrow Transplantation; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D017809:Fatal Outcome; D015774:Ganciclovir / Q000009:adverse effects* / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D012074:Remission Induction
D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015774:Ganciclovir